XML 15 R4.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Revenue    
Total revenue $ 26,504 $ 32,794
Costs and expenses    
Research and development 8,865 10,753
Selling, general and administrative 30,875 27,608
Total costs and expenses 54,007 52,114
Loss from operations (27,503) (19,320)
Interest expense (1,030) (887)
Loss on forward sale of Series B Preferred Stock (37,792) 0
Unrealized loss on bridge loans (10,655) 0
Other income (expense), net 118 (285)
Loss before income taxes (76,862) (20,492)
Income tax benefit 574 1,671
Net loss $ (76,288) $ (18,821)
Net loss per share, basic (in dollars per share) $ (0.99) $ (0.25)
Net loss per share, diluted (in dollars per share) $ (0.99) $ (0.25)
Shares used in computing net loss per share, basic (in shares) 77,031 74,707
Shares used in computing net loss per share, diluted (in shares) 77,031 74,707
Series B Preferred Stock    
Costs and expenses    
Loss on forward sale of Series B Preferred Stock $ (37,792) $ 0
Product revenue    
Revenue    
Total revenue 20,004 24,728
Costs and expenses    
Cost of revenue 12,339 11,663
Service    
Revenue    
Total revenue 6,144 6,286
Costs and expenses    
Cost of revenue 1,928 2,090
Development revenue    
Revenue    
Total revenue 88 1,480
Other revenue    
Revenue    
Total revenue $ 268 $ 300